Drug Profile


Alternative Names: HTF 919; SDZ HTF 919; Zelmac; Zelnorm

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Gastrokinetics; Indoles; Irritable bowel syndrome therapies
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Discontinued Dyspepsia; Gastro-oesophageal reflux

Most Recent Events

  • 27 Jul 2007 A restricted access programme has been established for tegaserod in the US for patients with Constipation with or without Irritable bowel syndrome
  • 08 Jun 2007 Withdrawn for Irritable bowel syndrome in China (PO)
  • 01 Jun 2007 Data presented at Digestive Disease Week 2007 (DDW-2007) added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top